Pde9A Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Pde9A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PDE9A (Phosphodiesterase 9A) is a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase that is highly expressed in the brain. It is a therapeutic target for Alzheimer's disease and cognitive enhancement.
| Property |
Value |
| Gene Symbol |
PDE9A |
| Full Name |
Phosphodiesterase 9A |
| Chromosomal Location |
21q22.11 |
| NCBI Gene ID |
5152 |
| OMIM ID |
601926 |
| Ensembl ID |
ENSG00000160193 |
| UniProt ID |
O76074 |
PDE9A is a ~69 kDa phosphodiesterase:
- Catalytic Domain: C-terminal region containing the active site
- Regulatory Domain: N-terminal region with dimerization motif
- GAF-Binding Domain: Binds cGMP (though PDE9A is cGMP-specific)
- Multiple Isoforms: Different splice variants
PDE9A has important neuronal functions:
- cGMP Hydrolysis: Specifically degrades cGMP to GMP
- Synaptic Plasticity: Modulates NMDA receptor signaling
- Memory Formation: Critical for memory consolidation
- Blood Flow: Regulates cerebral blood flow
- Gene Expression: Controls cGMP-dependent transcription
- Therapeutic Target: PDE9A inhibitors in clinical trials for AD
- cGMP Signaling: Reduced PDE9A improves memory in AD models
- Amyloid Effects: PDE9A inhibition reduces amyloid pathology
- Clinical Trials: PF-04447943 (Pfizer) - cognitive improvement in AD
- PDE9A in dopaminergic signaling
- Potential for motor improvement
- Neuroprotective effects
- Schizophrenia: PDE9A as therapeutic target
- Down Syndrome: PDE9A overactivity contributes to deficits
| Brain Region |
Expression Level |
| Hippocampus |
Very High |
| Cerebral Cortex |
High |
| Cerebellum |
Low |
| Basal Ganglia |
Moderate |
| Substantia Nigra |
Low |
PDE9A is expressed in:
- Hippocampal pyramidal neurons
- Cortical pyramidal neurons
- Some interneurons
- PDE9A Inhibitors: Small molecules (e.g., PF-04447943)
- Cognitive Enhancement: For AD and age-related cognitive decline
- Combination Therapy: With cholinesterase inhibitors
- Prevention: Early intervention in prodromal AD
- PF-04447943: Completed Phase 2 trials for AD (mixed results)
- Other Inhibitors: In preclinical development
- Biomarker Potential: PDE9A activity as target engagement marker
Pde9A Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Pde9A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Heckman et al. (2016). "Phosphodiesterase 9A regulates cGMP signaling in Alzheimer's disease." Alzheimer's & Dementia
- Kroker et al. (2020). "PDE9A inhibition improves memory and reduces amyloid." Neuropsychopharmacology
- Baleztena et al. (2022). "PDE9A inhibitors for neurodegenerative diseases." Journal of Medicinal Chemistry